Proteins

Screening Libraries

Product Data Sheet

JFD00244

Cat. No.: HY-108986

CAS No.: 96969-83-4 Molecular Formula: $C_{30}H_{26}N_{2}O_{4}$ Molecular Weight: 478.54

Target: Sirtuin; SARS-CoV

Pathway: Cell Cycle/DNA Damage; Epigenetics; Anti-infection

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 6 months

> -20°C 1 month

SOLVENT & SOLUBILITY

In Vitro DMSO: 50 mg/mL (104.48 mM; Need ultrasonic)

H₂O: < 0.1 mg/mL (ultrasonic; warming; heat to 60°C) (insoluble)

	Solvent Mass Concentration	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.0897 mL	10.4484 mL	20.8969 mL
otock ootations	5 mM	0.4179 mL	2.0897 mL	4.1794 mL
	10 mM	0.2090 mL	1.0448 mL	2.0897 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.08 mg/mL (4.35 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description	JFD00244 is a sirtuin 2	(SIRT2) inhibitor, with anti-tumor effect. JFD00244 is also a Nsp-16 inhibitor against SARS-CoV-2 ^{[1][2]} .
IC ₅₀ & Target	SIRT2 ^[1] ;SARS-CoV-2 ^[2]	
In Vitro	(DU145), respectively ^{[3}	M ; 48 h) inhibits cell growth against prostate cancer cell lines with IC ₅₀ s of 200 nM (22Rv1) and 1 μ M l. ently confirmed the accuracy of these methods. They are for reference only.
	Cell Line:	22Rv1 and DU145 cells

Concentration:	50 nM, 100 nM, 200 nM, 500 nM, 1 μM, 5 μM, 10 μM, 50 μM
Incubation Time:	48 hours
Result:	Inhibited prostate cancer cell lines siginificantly.

REFERENCES

- [1]. Shankar U, et al. Potential Drugs Targeting Nsp16 Protein May Corroborates a Promising Approach to Combat SARSCoV-2 Virus. ChemRxiv. Cambridge: Cambridge Open Engage; 2020; This content is a preprint and has not been peer-reviewed.
- [2]. Kim Dae Jung, et al. Pharmaceutical composition for preventing and treating prostate cancer: World Intellectual Property Organization, WO2014065537[P]. 2014-05-01.
- [3]. Ciarlo C, A chemical screen in zebrafish embryonic cells establishes that Akt activation is required for neural crest development. Elife. 2017 Aug 23;6. pii: e29145.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech @ Med Chem Express.com$

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA